A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||A Compassionate Access Protocol For Those Patients Who Have Completed A4001029|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00801515
|Pfizer Investigational Site|
|Montreal, Quebec, Canada, H3G 1A4|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|